^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

Excerpt:
In 136 tamoxifen-treated patients, the 76-gene signature identified a group of patients with a poor prognosis [hazard ratio (HR), 4.62; P = 0.0248]. These patients showed a 12.3% absolute benefit of tamoxifen in 10-year DMFS (HR, 0.52; P = 0.0318) compared with untreated high-risk patients.
DOI:
10.1007/s10549-008-0183-2
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Comparison of Prognostic Signatures in Node-Negative Tamoxifen-Treated Breast Cancer Patients.

Excerpt:
All patients received tamoxifen only as adjuvant treatment after surgery…Cox regression analysis yielded a significant outcome association for all three gene signatures (76-gene signature: P = 0.0018; 97-gene signature: P = 0.0294; 21-gene signature: P = 0.0025) in the whole ESR1+/ERBB2– cohort.
DOI:
10.1158/0008-5472.SABCS-09-104